ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
Go back to ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data| (NASDAQ: IBRX) | Delayed: 8.75 -0.01 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.76 | 52 Week High | $ | |||
| Open | $8.72 | 52 Week Low | $ | |||
| Day High | $9.21 | P/E | N/A | |||
| Day Low | $8.61 | EPS | $ | |||
| Volume | 7,021,994 | |||||
